ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it will be presenting results from its clinical trial of ICT-107 at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago.

“Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107)”

Surasak Phuphanich, M.D., Director of the neuro-oncology program at the Cedars-Sinai Medical Center and the study's lead investigator, will present the poster titled, "Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107)", on Sunday, June 6th.

The abstract released by ASCO today incorrectly states that "The median progression-free survival time in this group was 13.7 months and RT/TMZ regimen 6.9 months (EORTC/NCIC)". This should have been as follows: The median progression-free survival time in the newly diagnosed patients was 17.7 months compared to RT/TMZ regimen of 6.9 months (EORTC/NCIC).

SOURCE ImmunoCellular Therapeutics, Ltd.